Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of IY-NS250 vs IY-NT-SR in Healthy Volunteers
NCT06725992Phase 1Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ilaprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Area Under the Curve at steady state over the dosing interval at Day 7 and Integrated Gastric Acidity at Day 7. Started Jan 2024; status: completed.
02
Drugs
ilaprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06725992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725992.